良性前列腺增生治疗市场－全球产业规模、份额、趋势、机会和预测，按药物治疗、手术治疗、最终用户、地区和竞争细分，2020 年至 2030 年

2024 年全球良性前列腺增生 (BPH) 治疗市场价值为 15.3 亿美元，预计到 2030 年将达到 25.1 亿美元，预测期内的复合年增长率为 8.75%。全球良性前列腺增生 (BPH) 治疗市场正在稳步增长，这得益于老龄化人口日益增多和泌尿健康意识不断提高。 BPH 是一种非癌性摄护腺增大，会导致不适的泌尿症状并严重影响生活品质。因此，对有效治疗方案的需求——从药物到微创手术和手术——正在各个地区不断扩大。根据世界卫生组织 (WHO) 的预测，到 2050 年，大约 80% 的老年人口将生活在中低收入国家。此外，预计 2020 年至 2050 年间 80 岁及以上人口的数量将增加两倍，达到近 4.26 亿。年龄是良性前列腺增生 (BPH) 的主要风险因素，其在老年男性中的盛行率显着上升。因此，全球老年人口的成长很可能在未来几年推动 BPH 治疗市场的大幅扩张，对有效诊断和管理解决方案的需求也将随之增加。

医疗技术的进步带来了创伤更小、恢復时间更短、疗效更佳的治疗方法，鼓励更多患者及时寻求介入。医药领域仍然是市场的重要组成部分，其中α受体阻断剂和5-α还原酶抑制剂是常用的处方药。同时，雷射疗法和其他能量疗法的兴起，透过提供更安全、副作用更少的替代方案，正在重塑外科手术格局。新兴经济体医疗基础设施的不断改进也促进了诊断和治疗的可近性，进一步推动了市场成长。生活方式的改变、医疗支出的增加以及泌尿外科领域的持续研发，正在推动良性前列腺增生（BPH）治疗的变革。全球良性前列腺增生（BPH）治疗市场着重于改善患者的舒适度和长期疗效，随着认知度的提升和技术创新的不断进步，市场规模有望持续扩张。

关键市场驱动因素

人口老化

主要市场挑战

先进治疗的成本高昂

主要市场趋势

转向微创手术

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球良性摄护腺增生 (BPH) 治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 药物治疗（α受体阻断剂、5-α还原酶抑制剂、磷酸二酯酶-5抑制剂）
  • 透过手术治疗（经尿道前列腺切除术（TURP）、前列腺尿道抬高术（PUL）、前列腺切除术、雷射手术、经尿道微波技术（TUMT）、经尿道前列腺针吸消融术（TUNA）以及其他（Rezum 疗法、Urolift 疗法等）
  • 按最终使用者（医院和诊所、门诊手术中心等）
  • 按地区（北美、欧洲、亚太、南美、中东和非洲）
  • 按公司分类（2024）
• 市场地图

第六章：北美良性摄护腺增生 (BPH) 治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 按地区 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲良性前列腺增生（BPH）治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太地区良性摄护腺增生 (BPH) 治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳洲

第九章：南美良性前列腺增生（BPH）治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲良性摄护腺增生 (BPH) 治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 阿联酋
  • 沙乌地阿拉伯
  • 南非

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

第 13 章：临床试验分析

第 14 章：竞争格局

• Boston Scientific Corporation
• Coloplast Corporation
• Teleflex Incorporated
• Olympus Corporation
• Glaxo Smith Kline PLC
• Eli Lily
• Abott Laboratories
• Medifocus Inc.
• Urologix, LLC
• Pfizer Inc

第 15 章：策略建议

第 16 章：关于我们与免责声明

Global Benign Prostate Hyperplasia (BPH) Treatment Market was valued at USD 1.53 billion in 2024 and is expected to reach USD 2.51 billion by 2030 with a CAGR of 8.75% during the forecast period. The global benign prostate hyperplasia (BPH) treatment market is experiencing steady growth, driven by the increasing prevalence of aging populations and rising awareness of urological health. BPH, a non-cancerous enlargement of the prostate gland, leads to uncomfortable urinary symptoms and significantly impacts quality of life. As a result, demand for effective treatment options-ranging from medication to minimally invasive procedures and surgery-is expanding across regions. According to World Health Organization (WHO) projections, by 2050, approximately 80% of the elderly population will live in low- and middle-income countries. Additionally, the number of individuals aged 80 and above is expected to triple between 2020 and 2050, reaching nearly 426 million. Age is the leading risk factor for benign prostatic hyperplasia (BPH), with its prevalence increasing significantly in older men. As a result, the growing global geriatric population is likely to drive substantial expansion in the BPH treatment market in the coming years, with heightened demand for effective diagnosis and management solutions.

Advancements in medical technology have introduced less invasive treatment methods with shorter recovery times and improved outcomes, encouraging more patients to seek timely intervention. The pharmaceutical segment remains a key part of the market, with alpha-blockers and 5-alpha-reductase inhibitors being commonly prescribed. Meanwhile, the rise of laser therapies and other energy-based treatments is reshaping the surgical landscape by offering safer alternatives with reduced side effects. Growing healthcare infrastructure in emerging economies is also fostering access to diagnosis and treatment, further propelling market growth. The lifestyle changes, increased healthcare expenditure, and ongoing research and development in urology are contributing to the evolution of BPH management. With a focus on improving patient comfort and long-term results, the global BPH treatment market is poised to continue expanding as both awareness and technological innovation advance.

Key Market Drivers

Aging Population

The aging population is one of the most significant and influential drivers of the global benign prostate hyperplasia (BPH) treatment market. For instance, according to WHO 2025, global life expectancy at birth reached 73.3 years in 2024, rising by 8.4 years since 1995. The population aged 60 and older is expected to grow from 1.1 billion in 2023 to 1.4 billion by 2030, with the trend accelerating notably in developing regions. As men age, the likelihood of developing BPH increases substantially, making age a primary risk factor for the condition. BPH is characterized by the non-cancerous enlargement of the prostate gland, which commonly affects men over the age of 50. This physiological change occurs due to hormonal fluctuations, particularly the imbalance between testosterone and dihydrotestosterone (DHT), which promotes prostate cell growth. Over time, this leads to the gradual thickening and growth of the prostate, often resulting in urinary symptoms such as increased frequency, urgency, and incomplete bladder emptying.

Globally, improvements in healthcare, nutrition, and living standards have significantly extended life expectancy. This demographic shift means a larger proportion of the population is entering age brackets where BPH is more prevalent. Consequently, the demand for diagnostic, pharmaceutical, and surgical interventions is increasing. Healthcare systems, especially in developed countries, are seeing a growing burden of age-related conditions, with BPH being a leading urological issue among elderly men.

As people live longer and prioritize quality of life in older age, there is greater willingness to seek treatment for chronic but manageable conditions like BPH. The aging population is also more likely to be covered by healthcare insurance or public health systems, which further facilitates access to treatment. In emerging economies, increasing awareness among the elderly and improvements in medical infrastructure are similarly boosting diagnosis and treatment rates.

As this demographic trend continues, it is expected that the prevalence of BPH will rise, placing sustained demand on healthcare providers and driving innovation in less invasive, more effective treatment solutions. In this context, the aging population not only fuels market growth but also shapes the evolution of therapeutic strategies and healthcare delivery models for BPH.

Key Market Challenges

High Cost of Advanced Treatments

The high cost of advanced treatments poses a significant challenge to the growth and accessibility of the global benign prostate hyperplasia (BPH) treatment market. As medical technology evolves, newer treatment modalities such as laser therapies (e.g., HoLEP, GreenLight), water vapor therapy (Rezum), and prostatic urethral lift (UroLift) have emerged as preferred options due to their minimally invasive nature, shorter recovery times, and reduced side effects. However, these benefits come at a considerable financial cost. The equipment required for these procedures is often expensive, and so are the associated operational and maintenance costs, which are ultimately passed on to the patients or healthcare systems.

In many countries, especially those with limited healthcare funding or weak insurance infrastructure, the affordability of such advanced treatments becomes a major barrier. Patients in low- and middle-income regions may be forced to rely on older, more invasive procedures or pharmacological therapies, even when newer options would offer better outcomes. The private healthcare settings tend to dominate the availability of these innovations, making them inaccessible to individuals relying on public health services.

This economic disparity not only limits patient access but also discourages widespread adoption by healthcare providers due to the high initial investment. In addition, inconsistent or inadequate reimbursement policies in many regions further restrict the uptake of newer treatment modalities, particularly in outpatient settings. Without broader financial support or cost reduction strategies, the high cost of advanced BPH treatments remains a key obstacle to ensuring equitable access and scaling the market globally.

Key Market Trends

Shift Toward Minimally Invasive Procedure

The shift toward minimally invasive procedures is one of the most prominent trends shaping the global benign prostate hyperplasia (BPH) treatment market. Traditionally, BPH treatment involved surgical interventions such as transurethral resection of the prostate (TURP), which, while effective, often required prolonged hospital stays, significant recovery time, and a higher risk of complications such as bleeding and sexual dysfunction. In contrast, minimally invasive procedures offer a less traumatic alternative with quicker recovery, fewer complications, and a reduced risk of side effects, making them increasingly popular among both patients and healthcare providers.

Technologies like laser therapy (e.g., Holmium Laser Enucleation of the Prostate, HoLEP), prostatic urethral lift (UroLift), and water vapor therapy (Rezum) have gained traction due to their ability to treat BPH with precision and efficiency. These treatments are performed using advanced instruments that can target the enlarged prostate tissue without the need for large incisions, leading to shorter hospital stays, faster recovery times, and less post-operative pain. As a result, many patients are opting for these procedures over traditional surgery, valuing the minimal downtime and reduced risks.

This shift also aligns with a broader trend in healthcare toward procedures that maximize patient comfort and minimize disruption to daily life. The growing popularity of minimally invasive treatments is driving innovation in the field, encouraging the development of more effective, less invasive therapies. As awareness of these alternatives spreads, the market for minimally invasive BPH treatments is expected to expand, offering more choices for patients and enhancing the overall treatment landscape.

Key Market Players

• Boston Scientific Corporation
• Coloplast Corporation
• Teleflex Incorporated
• Olympus Corporation
• Glaxo Smith Kline PLC
• Eli Lily
• Abott Laboratories
• Medifocus Inc.
• Urologix, LLC
• Pfizer Inc

Report Scope:

In this report, the Global Benign Prostate Hyperplasia (BPH) Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Benign Prostate Hyperplasia (BPH) Treatment Market, By Drug Treatment:

• Alpha Blockers
• 5-Alpha Reductase Inhibitors
• phosphodiesterase-5 inhibitors

Benign Prostate Hyperplasia (BPH) Treatment Market, By Surgical Treatment:

• Transurethral resection of the prostate (TURP)
• Prostatic Urethral Lift (PUL)
• Prostatectomy
• Laser Surgery
• Transurethral Microwave Technique (TUMT)
• Transurethral Needle Ablation of the Prostate (TUNA)
• Others

Benign Prostate Hyperplasia (BPH) Treatment Market, By End User:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Benign Prostate Hyperplasia (BPH) Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Benign Prostate Hyperplasia (BPH) Treatment Market.

Available Customizations:

Global Benign Prostate Hyperplasia (BPH) Treatment Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Benign Prostate Hyperplasia (BPH) Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Treatment (Alpha Blockers, 5-Alpha Reductase Inhibitors, and Phosphodiesterase-5 Inhibitors)
  • 5.2.2. By Surgical Treatment (Transurethral resection of the prostate (TURP), Prostatic Urethral Lift (PUL), Prostatectomy, laser surgery, Transurethral microwave Technique (TUMT), Transurethral needle ablation of the prostate (TUNA), and others (Rezum therapy, Urolift therapy, etc)
  • 5.2.3. By End User (hospitals and clinics, ambulatory surgical Centers, and Others)
  • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Benign Prostate Hyperplasia (BPH) Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Treatment
  • 6.2.2. By Surgical Treatment
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. By Region North America: Country Analysis
  • 6.3.1. United States Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Treatment
      • 6.3.1.2.2. By Surgical Treatment
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Treatment
      • 6.3.2.2.2. By Surgical Treatment
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Treatment
      • 6.3.3.2.2. By Surgical Treatment
      • 6.3.3.2.3. By End User

7. Europe Benign Prostate Hyperplasia (BPH) Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Treatment
  • 7.2.2. By Surgical Treatment
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Treatment
      • 7.3.1.2.2. By Surgical Treatment
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Treatment
      • 7.3.2.2.2. By Surgical Treatment
      • 7.3.2.2.3. By End User
  • 7.3.3.United Kingdom Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Treatment
      • 7.3.3.2.2. By Surgical Treatment
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Treatment
      • 7.3.4.2.2. By Surgical Treatment
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Treatment
      • 7.3.5.2.2. By Surgical Treatment
      • 7.3.5.2.3. By End User

8. Asia-Pacific Benign Prostate Hyperplasia (BPH) Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Treatment
  • 8.2.2. By Surgical Treatment
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Treatment
      • 8.3.1.2.2. By Surgical Treatment
      • 8.3.1.2.3. By End User
  • 8.3.2. Japan Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Treatment
      • 8.3.2.2.2. By Surgical Treatment
      • 8.3.2.2.3. By End User
  • 8.3.3. India Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Treatment
      • 8.3.3.2.2. By Surgical Treatment
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Treatment
      • 8.3.4.2.2. By Surgical Treatment
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Treatment
      • 8.3.5.2.2. By Surgical Treatment
      • 8.3.5.2.3. By End User

9. South America Benign Prostate Hyperplasia (BPH) Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Treatment
  • 9.2.2. By Surgical Treatment
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Treatment
      • 9.3.1.2.2. By Surgical Treatment
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Treatment
      • 9.3.2.2.2. By Surgical Treatment
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Treatment
      • 9.3.3.2.2. By Surgical Treatment
      • 9.3.3.2.3. By End User

10. Middle East and Africa Benign Prostate Hyperplasia (BPH) Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Treatment
  • 10.2.2. By Surgical Treatment
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Treatment
      • 10.3.1.2.2. By Surgical Treatment
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Treatment
      • 10.3.2.2.2. By Surgical Treatment
      • 10.3.2.2.3. By End User
  • 10.3.3. South Africa Benign Prostate Hyperplasia (BPH) Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Treatment
      • 10.3.3.2.2. By Surgical Treatment
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

13. Clinical Trial Analysis

• 13.1. Ongoing Clinical Trials
• 13.2. Completed Clinical Trials
• 13.3. Terminated Clinical Trials
• 13.4. Breakdown of Pipeline, By Development Phase
• 13.5. Breakdown of Pipeline, By Status
• 13.6. Breakdown of Pipeline, By Study Type
• 13.7. Breakdown of Pipeline, By Region
• 13.8. Clinical Trials Heat Map

14. Competitive Landscape

• 14.1. Boston Scientific Corporation
• 14.2. Coloplast Corporation
• 14.3. Teleflex Incorporated
• 14.4. Olympus Corporation
• 14.5. Glaxo Smith Kline PLC
• 14.6. Eli Lily
• 14.7. Abott Laboratories
• 14.8. Medifocus Inc.
• 14.9. Urologix, LLC
• 14.10.Pfizer Inc

15. Strategic Recommendations

16. About Us and Disclaimer